

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Madaline Chirica, et al.

Application No.: Not yet known.

Filed: Herewith

For: MAMMALIAN RECEPTOR
PROTEINS; RELATED
REAGENTS AND METHODS


Examiner: Not yet known.

Art Unit: Not yet known.

"Express Mailing" mailing label number EL 982 851 001 US
Date of Deposit: November 21 2003

I hereby certify that this correspondence is being deposited with
the United States Postal Service "Express Mail Post to
Addressee" service under 37 CFR 1.10 on the date indicated
above and is addressed to: Mail Stop Patent Application,
Commissioner for Patents, P.O. Box 1450, Alexandria, VA
22313-1450.

by:


Tom Brody

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**COMPLIANCE WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Honorable Sir:

In order to comply with requirements for patent applications containing
nucleotide sequence and/or amino acid sequence disclosures, for the above-identified
application, in accordance with 37 C.F.R. §§1.821-1.825, Applicants hereby submit:
(1) a write-protected diskette containing a computer-readable submission for the
"Sequence Listing;" and (2) a "Sequence Listing" paper copy of the contents of the
diskette.

REMARKS

Enclosed is a write-protected floppy diskette with the sequence listing generated
by the Patent Office's PATENTIN program. The diskette should comply with the
requirements of 37 C.F.R. §1.824 and is IBM PC compatible with a PC-DOS/MS-DOS

operating system. If the diskette is damaged, please call Applicants and a replacement diskette will be provided. A paper copy printout of the diskette is attached thereto.


I hereby state that the informational contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §§1.821(c) and (e), respectfully, are believed to be the same. This submission introduces no new matter, since the enclosed sequences are all disclosed in the Sequence Listing submitted in the priority document, U.S. Ser. No. 09/853,180, filed May 10, 2001.

Applicants have invested significant labor and care in preparing the present submission. The enclosed items are a bona fide effort to bring the present application in full compliance with the rules for sequence submissions. Should this not be the case, Applicants respectfully request notification of specific deficiencies and an opportunity for remedy, as described in 37 C.F.R. §1.135(c).

Applicants believe that no fees are required; however, if any fees are required with the present submission, the Commissioner is authorized to charge any fees or credit any overpayment to DNAX Research Institute Deposit Account No. 04-1239.

Respectfully submitted,

Date: November 21, 2003

By: 
Tom Brody
Agent for Applicants
Reg. No. 46,433

Customer No. 028008

DNAX Research, Inc.
901 California Avenue
Palo Alto, CA 94304-1104
Telephone (Switchboard): (650) 496-6400
Telephone No. (Direct): (650) 496-1244
Facsimile No.: (650) 496-1200

Enclosed: Paper copy of the present Sequence Listing (15 pages).